Labetalol: response and safety in critically ill hemorrhagic stroke patients

Ann Pharmacother. 1993 Feb;27(2):180-1. doi: 10.1177/106002809302700209.


Objective: To observe and characterize the blood pressure (BP)-lowering and adverse hemodynamic and/or central nervous system effects of intravenous bolus doses of labetalol in hemorrhagic stroke patients.

Design: Observational, prospective, pilot survey conducted over an eight-week period.

Setting: Surgical intensive care unit.

Participants: Patients admitted with an intracerebral or subarachnoid hemorrhage.

Main outcome parameters: Absolute decline in systolic BP (SBP) and diastolic BP (DBP), time to peak reduction in SBP and DBP, and adverse hemodynamic and mental status changes.

Results: Labetalol at doses between 5 and 25 mg lowered SBP by 6-19 percent (baseline 152-184 mm Hg) and DBP by 3-26 percent (baseline 50-99 mm Hg). Adverse hemodynamic or mental status changes were not detected following labetalol administration.

Conclusions: Small (< or = 25 mg) intravenous bolus doses of labetalol produce mild decreases in BP in hemorrhagic stroke patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Blood Pressure / drug effects*
  • Cerebral Hemorrhage / drug therapy*
  • Cerebrovascular Disorders / drug therapy*
  • Critical Illness
  • Female
  • Humans
  • Injections, Intravenous
  • Intensive Care Units
  • Labetalol / administration & dosage
  • Labetalol / adverse effects
  • Labetalol / pharmacology
  • Labetalol / therapeutic use*
  • Male
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Subarachnoid Hemorrhage / drug therapy


  • Labetalol